Prosecution Insights
Prosecution Insights
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DEVI, SARVAMANGALA | 1 | 65.4% | +55.1% |
| DRISCOLL, MAUREEN VARINA | 1 | 64.2% | +43.7% |
| BARRERA, IMMACULADA | 1 | 34.6% | +77.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17927804 | SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) POLYPEPTIDES AND USES THEREOF FOR VACCINE PURPOSES | BARRERA, IMMACULADA | 50d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17927804 | SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) POLYPEPTIDES AND USES THEREOF FOR VACCINE PURPOSES | BARRERA, IMMACULADA | 50d overdue |
| 18253493 | ANTI-CD25 ANTIBODIES | DRISCOLL, MAUREEN VARINA | 46d overdue |
| 18269113 | CHLAMYDIA VACCINE BASED ON TARGETING MOMP VS4 ANTIGEN TO ANTIGEN PRESENTING CELLS | DEVI, SARVAMANGALA | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1644 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18269113 | CHLAMYDIA VACCINE BASED ON TARGETING MOMP VS4 ANTIGEN TO ANTIGEN PRESENTING CELLS | DEVI, SARVAMANGALA | 1645 | §112DP | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18253493 | ANTI-CD25 ANTIBODIES | DRISCOLL, MAUREEN VARINA | 1644 | §112 | Final Rejection | 46d overdue | Pending | May 18, 2023 |
| 17927804 | SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) POLYPEPTIDES AND USES THEREOF FOR VACCINE PURPOSES | BARRERA, IMMACULADA | 1671 | §103§112 | Final Rejection | 50d overdue | Pending | Nov 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial